Aurinia Pharmaceuticals (NASDAQ:AUPH) Announces Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) posted its earnings results on Thursday. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.08, reports. The business had revenue of $67.77 million for the quarter, compared to analysts’ expectations of $59.07 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%.

Aurinia Pharmaceuticals Stock Down 0.2 %

AUPH opened at $8.32 on Friday. The firm’s 50 day simple moving average is $7.13 and its two-hundred day simple moving average is $6.12. The company has a market capitalization of $1.19 billion, a PE ratio of -55.47 and a beta of 1.45. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.05. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AUPH. StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its position in Aurinia Pharmaceuticals by 12.0% during the first quarter. BNP Paribas Financial Markets now owns 78,466 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 8,398 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in shares of Aurinia Pharmaceuticals during the 1st quarter valued at approximately $158,000. Nordea Investment Management AB increased its holdings in Aurinia Pharmaceuticals by 51.7% in the 1st quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock worth $1,552,000 after acquiring an additional 105,100 shares in the last quarter. ProShare Advisors LLC raised its stake in Aurinia Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 2,873 shares during the period. Finally, Jupiter Asset Management Ltd. lifted its holdings in Aurinia Pharmaceuticals by 21.3% during the first quarter. Jupiter Asset Management Ltd. now owns 247,052 shares of the biotechnology company’s stock valued at $1,238,000 after purchasing an additional 43,366 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.